Investors Scrutinize Disc Medicine Following FDA Rejection

The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, effectively denying the approval of its new drug application. Federal officials cited significant uncertainties within the filing that required additional evidence, halting the firm's progress on the bitopertin program. This rejection wiped out nearly a quarter of the company's market value in a single trading session.

Rosen Law is now organizing a prospective class action lawsuit to recover losses for those who held shares during the period in question. The firm operates on a contingency basis, meaning participants incur no out-of-pocket costs. Investors seeking to join the action or provide documentation are encouraged to contact Phillip Kim at 866-767-3653 or submit details through the firm’s online portal.